Bioceres Crop Solutions Corp. logo

Bioceres Crop Solutions Corp.

BIOX

NASDAQBasic MaterialsAgricultural Inputs

Regular session

$0.4279

−$0.013 · -2.95%

Aug 24, 10:15 AM ET

BIOX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

19

Strong Down

Sentiment

40

Bearish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Bioceres Crop Solutions Corp. (BIOX) is a company dedicated to enhancing agricultural output through a diverse range of solutions. Its operations are organized into three principal divisions. The Seed and Integrated Products segment is responsible for creating and bringing to market cutting-edge seed technologies, genetic material, biotechnological innovations, and specialized seed coatings. Under its Crop Protection segment, the company formulates, manufactures, and distributes a comprehensive array of products, including Rizoderma, various adjuvants, therapeutic agents, weed killers, insect eradicators, fungal treatments, and pest lures. The Crop Nutrition unit focuses on the development, production, and distribution of inoculants, bio-stimulants, and both organic and micro-granular fertilizers. A notable offering from Bioceres is HB4, an innovative seed technology engineered for drought resistance. The enterprise maintains a significant presence across several countries, including Argentina, Uruguay, France, and South Africa, alongside broader international operations. Established in 2001, the firm's main offices are situated in Rosario, Argentina. Bioceres Crop Solutions Corp. functions as a subsidiary entity under the umbrella of Bioceres LLC.

Industry
Agricultural Inputs
Sector
Basic Materials
Headquarters
AR
CEO
Federico Trucco
Listed since
Mar 22, 2018
Employees
751

Market position

Day range

Current $0.4279

52-week range

Current $0.4279

Open
$0.44
Previous close
$0.4409
Volume
22.97K
0.09× average
Average volume
247.43K
Average daily volume
Market cap
27.06M USD
Beta
0.4
Market reference 1
50-day average
$0.3669
+16.63% above average
200-day average
$0.7566
-43.45% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.11×
P/B (TTM)
0.43×
P/S (TTM)
0.1×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
36.71%
Operating margin
0.82%
Net margin
-95.02%

Financial health

Debt / equity
3.76×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends50%26%2%-23%Gross margin, FY2021: 43.97%Gross margin, FY2022: 38.49%Gross margin, FY2023: 42.97%Gross margin, FY2024: 39.07%Gross margin, FY2025: 38.44%Operating margin, FY2021: 18.57%Operating margin, FY2022: 12.14%Operating margin, FY2023: 12.92%Operating margin, FY2024: 9.64%Operating margin, FY2025: -0.23%Net margin, FY2021: -3.32%Net margin, FY2022: -2.19%Net margin, FY2023: 4.48%Net margin, FY2024: 0.70%Net margin, FY2025: -16.62%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 43.97%. Gross margin FY2022 38.49%. Gross margin FY2023 42.97%. Gross margin FY2024 39.07%. Gross margin FY2025 38.44%. Operating margin FY2021 18.57%. Operating margin FY2022 12.14%. Operating margin FY2023 12.92%. Operating margin FY2024 9.64%. Operating margin FY2025 -0.23%. Net margin FY2021 -3.32%. Net margin FY2022 -2.19%. Net margin FY2023 4.48%. Net margin FY2024 0.70%. Net margin FY2025 -16.62%.

Income trends

Revenue

333.34M USD-28.29%

Operating income

−761.9K USD−45.58M USD

Net income

−55.42M USD−58.66M USD
Income trends across reported periods516.85M USD308.76M USD100.66M USD−107.44M USDRevenue, FY2021: 206.7M USDRevenue, FY2022: 328.46M USDRevenue, FY2023: 419.45M USDRevenue, FY2024: 464.83M USDRevenue, FY2025: 333.34M USDOperating income, FY2021: 38.38M USDOperating income, FY2022: 39.87M USDOperating income, FY2023: 54.18M USDOperating income, FY2024: 44.82M USDOperating income, FY2025: −761.9K USDNet income, FY2021: −6.87M USDNet income, FY2022: −7.2M USDNet income, FY2023: 18.78M USDNet income, FY2024: 3.24M USDNet income, FY2025: −55.42M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 206.7M USD. Revenue FY2022 328.46M USD. Revenue FY2023 419.45M USD. Revenue FY2024 464.83M USD. Revenue FY2025 333.34M USD. Operating income FY2021 38.38M USD. Operating income FY2022 39.87M USD. Operating income FY2023 54.18M USD. Operating income FY2024 44.82M USD. Operating income FY2025 −761.9K USD. Net income FY2021 −6.87M USD. Net income FY2022 −7.2M USD. Net income FY2023 18.78M USD. Net income FY2024 3.24M USD. Net income FY2025 −55.42M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue333.34M USD464.83M USD419.45M USD328.46M USD206.7M USD
Cost of goods sold205.19M USD283.24M USD239.2M USD202.02M USD115.82M USD
Gross profit128.15M USD181.59M USD180.25M USD126.44M USD90.88M USD
Research and development14.91M USD17.18M USD15.35M USD6.95M USD5.62M USD
Selling, general, and administrative88.35M USD94.27M USD85.54M USD57.36M USD44.39M USD
Operating expenses128.91M USD136.77M USD111.76M USD84.91M USD49.97M USD
Interest expense25.63M USD26.87M USD23.79M USD17.93M USD21.24M USD
Depreciation and amortization22.18M USD21.3M USD19.39M USD9.19M USD6.26M USD
Operating income−761.9K USD44.82M USD54.18M USD39.87M USD38.38M USD
Net income−55.42M USD3.24M USD18.78M USD−7.2M USD−6.87M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.00

1769.60% upside
Past 12 months12-month forecastHigh $15.00Average $8.00Low $2.00

Rating distribution

5 ratings
Strong buy00%
Buy480%
Hold120%
Sell00%
Strong sell00%

BIOX news

BIOX peers

ETFs holding BIOX

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research BIOX

research.disclaimer